- Home
- CLDI vs SYNX Comparison
CLDI vs SYNX Comparison
Compare CLDI & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- SYNX
- Stock Information
- Founded
- CLDI 2014
- SYNX 2005
- Country
- CLDI United States
- SYNX Israel
- Employees
- CLDI N/A
- SYNX N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- SYNX
- Sector
- CLDI Health Care
- SYNX
- Exchange
- CLDI Nasdaq
- SYNX Nasdaq
- Market Cap
- CLDI 8.7M
- SYNX 10.2M
- IPO Year
- CLDI N/A
- SYNX 2024
- Fundamental
- Price
- CLDI $1.49
- SYNX $1.47
- Analyst Decision
- CLDI
- SYNX
- Analyst Count
- CLDI 0
- SYNX 0
- Target Price
- CLDI N/A
- SYNX N/A
- AVG Volume (30 Days)
- CLDI 231.9K
- SYNX 25.1K
- Earning Date
- CLDI 11-07-2025
- SYNX 09-26-2025
- Dividend Yield
- CLDI N/A
- SYNX N/A
- EPS Growth
- CLDI N/A
- SYNX N/A
- EPS
- CLDI N/A
- SYNX N/A
- Revenue
- CLDI N/A
- SYNX $6,003,000.00
- Revenue This Year
- CLDI N/A
- SYNX $32.35
- Revenue Next Year
- CLDI N/A
- SYNX N/A
- P/E Ratio
- CLDI N/A
- SYNX N/A
- Revenue Growth
- CLDI N/A
- SYNX N/A
- 52 Week Low
- CLDI $1.10
- SYNX $1.37
- 52 Week High
- CLDI $46.68
- SYNX $6.49
- Technical
- Relative Strength Index (RSI)
- CLDI 47.51
- SYNX 42.68
- Support Level
- CLDI $1.10
- SYNX $1.40
- Resistance Level
- CLDI $1.56
- SYNX $1.69
- Average True Range (ATR)
- CLDI 0.14
- SYNX 0.08
- MACD
- CLDI 0.01
- SYNX -0.02
- Stochastic Oscillator
- CLDI 69.49
- SYNX 38.17
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.